Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery

• Status: Terminated
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine whether ranibizumab therapy before and after tube insertion for glaucoma surgeries can maintain the patency of the tube and prevent scar formation, and increase the chances for a successful procedure compared to observation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Collaborator: Genentech, Inc.
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

1. ability to provide written informed consent and comply with study assessment for the full duration of the study.

2. age ≥ 21

3. diagnosis of glaucoma and determined to be candidate for therapy with tube insertion.

Exclusion Criteria:

1. pregnant or lactating females

2. Persons on oral contraceptives and women of child-bearing age

3. prior enrollment in the study

4. any conditions the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated

5. participation in another simultaneous medical investigation or trial

6. history of active inflammatory, infectious, or idiopathic keratitis precluding view of anterior segment structures

7. previous injections of ranibizumab in either eye.

8. Persons on Plavix (clopidogrel bisulfate) and coumadin

9. Persons with uncontrolled high blood pressure

10. Persons with renal or liver disease